Datapoint: Skyrizi Snags Psoriatic Arthritis Approval

The FDA last week approved AbbVie’s Skyrizi for the treatment of adults with active psoriatic arthritis. The news comes just days after Rinvoq, another AbbVie drug, scored an atopic dermatitis win. This will be the monoclonal antibody’s second indication. For the treatment of psoriasis, Skyrizi holds covered or better status for 98% of all insured lives in the U.S. Under the pharmacy benefit, 36% of covered lives have preferred access to Skyrizi.

SOURCE: MMIT Analytics, as of 1/26/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 26

Datapoint: Elevance Health to Acquire BCBS Louisiana

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 25

Datapoint: Seagen Scores Colorectal Cancer Nod for Tukysa

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 24

Datapoint: Georgia Doubles Down on Partial Medicaid Expansion Waiver

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today